Skip to main content

LAVA Therapeutics N.V. (LVTX)

NASDAQ: LVTX · Delayed Price · USD
6.59
+0.48 (7.86%)
After-hours:Sep 17, 2021 4:26 PM EDT
6.11
-0.22 (-3.48%)
At close: Sep 17, 4:00 PM
Market Cap157.49M
Revenue (ttm)4.41M
Net Income (ttm)n/a
Shares Out25.78M
EPS (ttm)-5.12
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume77,350
Open6.25
Previous Close6.33
Day's Range6.11 - 6.58
52-Week Range5.50 - 17.20
Betan/a
Analystsn/a
Price Target23.00 (+276.4%)
Est. Earnings DateNov 15, 2021

About LVTX

LAVA Therapeutics is a biotechnology company focused on transforming cancer treatment by developing a platform of novel bispecific antibodies engineered to selectively induce gamma-delta T cell-mediated immunity against tumor cells. Our approach activates Vg9Vd2 T cells, a specific and relatively abundant gamma-delta effector T cell subset, upon cross-linking to a selected tumor target by our bispecific gamma-delta T cell engagers, or gamma-delta bsTCEs. These cells have the natural ability to distinguish tumor cells from healthy cells. Activat...

IndustryBiotechnology
IPO DateMar 25, 2021
CEOStephen Hurly
Employees28
Stock ExchangeNASDAQ
Ticker SymbolLVTX
Full Company Profile

Financial Performance

Financial numbers in millions EURFinancial Statements

News

LAVA Therapeutics Provides Business Update and Reports Second Quarter Results

Enrollment continues in Phase 1/2a trial evaluating LAVA-051 in hematological malignancies

1 month ago - GlobeNewsWire

LAVA Therapeutics Announces Treatment of First Patient in Phase 1/2a Clinical Trial of LAVA-051 for Multiple Hematolo...

LAVA's first-in-class gamma-delta bsTCE to be evaluated as a treatment for chronic lymphocytic leukemia, multiple myeloma and acute myeloid leukemia LAVA's first-in-class gamma-delta bsTCE to be evaluat...

2 months ago - GlobeNewsWire

Ysios Capital Closes its Third Fund at €216 Million ($260 Million)

SAN SEBASTIÁN & BARCELONA, Spain--(BUSINESS WIRE)--Ysios Capital, Spain's largest and leading European venture capital firm specialised in the biotechnology sector, announces today that it has closed it...

3 months ago - Business Wire

LAVA Therapeutics to Present at 2021 Jefferies Virtual Healthcare Conference

UTRECHT, The Netherlands and PHILADELPHIA, May 25, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a biotechnology company focused on applying its expertise in bispecific gamma-delta T c...

3 months ago - GlobeNewsWire

LAVA Therapeutics Provides Business Update and Reports First Quarter Financial Results

IPO bolsters balance sheet to $160 million in cash and cash equivalents; expected to fund operations at least into the second half of 2023

4 months ago - GlobeNewsWire

LAVA Therapeutics to Present at 2021 UBS Global Healthcare Virtual Conference

UTRECHT, The Netherlands and PHILADELPHIA, May 18, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a biotechnology company focused on applying its expertise in bispecific gamma-delta T c...

4 months ago - GlobeNewsWire

LAVA Therapeutics Appoints Karen J. Wilson to its Board of Directors

UTRECHT, The Netherlands and PHILADELPHIA, April 01, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a biotechnology company focused on applying its expertise in bispecific gamma-delta T...

5 months ago - GlobeNewsWire

LAVA Therapeutics Announces Pricing of Initial Public Offering

UTRECHT, The Netherlands and PHILADELPHIA, March 24, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics B.V. (Nasdaq: LVTX), a biotechnology company focused on applying its expertise in bispecific gamma-delta T...

5 months ago - GlobeNewsWire

Dutch cancer biotech LAVA Therapeutics files for a $100 million US IPO

LAVA Therapeutics, a Dutch Phase 1/2a biotech developing novel bispecific antibodies for cancer, filed on Tuesday with the SEC to raise up to $100 million in an initial public offering.

6 months ago - NASDAQ

LAVA Therapeutics IPO Registration Document (S-1)

LAVA Therapeutics N.V. has filed to go public with an IPO on the NASDAQ.

6 months ago - SEC